Pharmaceuticals

Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included in the list of eligible securities under t...

2026-09-07 12:15 3251

Ddrops® Brings Medical Experts from Damansara Specialist Hospital and Motherhood.com.my Together in Malaysia for Science-Backed Vitamin D Forum

KUALA LUMPUR, Malaysia, Sept. 7, 2026 /PRNewswire/ -- Ddrops® brought together Damansara Specialist Hospital , recognised among the World's Best Hospitals (2026) powered by Statista, and Motherhood.com.my

2026-09-07 12:00 3187

CART Blood Pressure Monitor Demonstrates Utility in BP Monitoring for AF and Heart Failure Patients

- First to demonstrate clinical utility of ring-type BP monitoring in AF and heart failure patients - Highlighted CART blood pressure monitor's multifaceted value, including ESH-based validation and sleep apnea tracking MUNICH and SEOUL, South Korea, Sept. 7, 2026 /PRNewswire/ -- Sky Labs (CEO J...

2026-09-07 08:00 2080

AtomVie Global Radiopharma Celebrates the Grand Opening of its New State-of-the-Art Radiopharmaceutical Manufacturing Facility in Hamilton, Ontario

HAMILTON, ON, Sept. 5, 2026 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, today celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing facility at...

2026-09-05 00:29 4062

DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES

* Dimerix successfully enters into non-dilutive facility agreements to access A$34 million[1] with a syndicate of Australian and U.S. independent lenders, including the previously announced initial facility of A$10 million[2] * Facility terms for all Lenders substantially consistent with the p...

2026-09-04 11:00 4228

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept. 3, 2026 /PRNewswire/ -- TraceLink, the world's largest Agentic Business Net...

2026-09-03 22:00 2853

ClinHope Officially Establishes Hong Kong Branch to Strengthen Asia-Pacific Market Presence

TAIPEI, Sept. 3, 2026 /PRNewswire/ -- ClinHope today announced the official establishment of its Hong Kong branch. Following its operations in Taiwan and the United States, this marks another step in expanding into the Asian market and deepening its global service footprint. As the biotech, phar...

2026-09-03 16:09 2289

Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults

SHANGHAI, Sept. 3, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China's National Medical Product...

2026-09-03 13:20 3099

The Galien Foundation Announces the Nominees for the Inaugural 2026 Prix Galien Korea Awards

Historic First Edition Launches in Partnership with MK Media (Maekyung), Yozma Group Korea, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), and KoreaBIO at the World Knowledge Forum in Seoul SEOUL, South Korea, Sept. 3, 2026 /PRNewswire/ -- The Galien Foundation, the p...

2026-09-03 08:00 2747

EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

PROVIDENCE, R.I., Sept. 3, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements toISPRI™ , its proprietary in sili...

2026-09-02 23:19 2139

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ -- NovaGo Therapeutics AG, a ...

2026-09-02 18:00 2960

Despite nationwide basic stroke treatment coverage, delays accessing advanced stroke care in Vietnam vary by region, new report finds

Patients in Vietnam's Southwest region and Mekong Delta can travel up to ten hours for advanced stroke care; Vietnamese experts point to a public-private model in Can Tho as a way to close that gap. HO CHI MINH CITY, Vietnam, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach a...

2026-09-02 15:00 4927

Workforce shortages and limited public hospital capacity remain major barriers to stroke care in the Philippines, new report finds

Filipino experts call for equipping more public hospitals with advanced imaging technology, stronger EMS infrastructure and greater investment in specialist training to close these gaps MANILA, Philippines, Sept. 2, 2026 /PRNewswire/ -- Workforce shortages and limited public hospital capacity re...

2026-09-02 15:00 5273

Delays before patients reach stroke centres remain a major barrier to timely treatment in Malaysia, new report finds

Malaysia experts call for better public awareness of stroke symptoms, standardised hospital imaging protocols and expanded access to specialist care beyond major urban centres KUALA LUMPUR, Malaysia, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach stroke centres remain a maj...

2026-09-02 15:00 5751

Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds

New research commissioned by Siemens Healthineers shows transportation delays, slow reporting processes as leading barriers to timely stroke diagnosis. * Stronger referral networks, public awareness, AI-enabled diagnostics, coordinated care are key to strengthening stroke system readiness acros...

2026-09-02 15:00 5315

HEC Group Enters Strategic Partnerships in Macau to Advance the Internationalization of Cordyceps Sinensis

MACAU, Sept. 2, 2026 /PRNewswire/ -- HEC Group has entered into strategic partnerships with MCCY Science & Greater Health Manufactory (operating regionally as Seed Scientific Research International Limited) and Longtai Health to strengthen the production, commercialization and international deve...

2026-09-02 10:00 2568

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...

2026-09-02 09:27 2383

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026

Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical  (SHA: 688139) showcased a portfolio of automated and digital solutions sp...

2026-09-01 22:50 3592

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...

2026-09-01 19:30 2355

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...

2026-09-01 19:15 2588
1 ... 45678910 ... 184